Quinoprazine 

Quinoprazine is a potent inhibitor of Vaccinia virus DNA synthesis with an IC₅₀ value of 10 μM. Quinoprazine has antimalarial activity against Plasmodium berghei and also displays antiprion potency, significantly decreases PrP^Sc levels^[1]-[5].

Vaccinia virus DNA synthesis^[2]

Quinoprazine shows antimalarial action against Plasmodium berghei, the chloroquine-resistant isolate LN-K65^[1].
Quinoprazine blocks Vaccinia Virus infection by inhibiting DNA synthesis^[2].
Quinoprazine (IND2118) displays good antiprion potency and inhibits baseline PrP^Sc with reducing rates of 76% (dividing cells) and 51% (nondividing cells), respectively. Reducing PrP^Sc levels by >30% is considered to have good antiprion potency^[3][4].
Quinoprazine (IND2118) shows low cytotoxicity with reducing rates of 25% (dividing cells) and 24% (nondividing cells), respectively. Reducing cells <30% is considered to have a safe effect^[3][4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Quinoprazine is a 1-alkyl-4-[4-(heterylamino)phenyl]piperazines derivate, Quinoprazine (0.25 g/kg; i.p.; single dose) suppresses the growth of larvocysts of Echinococcus multilocularis in cotton rats^[5].
Quinoprazine (0.2-0.5 g/kg; p.o.; single dose) acts against the adult Hymenolepis nana. Exptl. and cures infected mice radically^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

382.50

C₂₅H₂₆N₄

115618-99-0

CCN(CC1)CCN1C(C=C2)=CC=C2NC3=C4C=C5C=CC=CC5=CC4=NC=C3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Mikhaĭlitsyn FS, et al. The search for new antiparasitic agents. 10. The synthesis, toxicological and antimalarial properties of nitrogen-containing heterocycles with a 4-(4-alkylpiperazinyl-1) phenylamine substituent (the preparation quinoprazine). Med P  [Content Brief]

  [2]. Ricciardi RP, et al. Therapeutic compounds for blocking DNA synthesis of POX viruses: United States, US20100035887[P]. 2010-02-11.

  [3]. Renslo AR, et al. Preparation of antiprion compounds containing thiazole-amine for treating neurodegenerative diseases: World Intellectual Property Organization, WO2013033037[P]. 2013-03-07.

  [4]. Silber BM, et al. Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells. Bioorg Med Chem. 2013 Dec 15;21(24):7999-8012.  [Content Brief]

  [5]. Mikhaĭlitsyn FS, et al. The search for new antiparasitic agents. 8. The synthesis and study of the acute toxicity, anti-alveolar hydatid and antihymenolepiasis activity of 1-alkyl-4[4-(heterylamino)phenyl]piperazines]. Med Parazitol (Mosk). 1991 Sep-Oct;(  [Content Brief]